Noufal Noha R, Yousef Einas M, Taha Mohamed
Department of Basic Medical Science, College of Medicine, Dar Al Uloom University, Riyadh, Saudi Arabia.
Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
J Pathol Transl Med. 2025 Sep;59(5):291-305. doi: 10.4132/jptm.2025.06.06. Epub 2025 Sep 8.
Prostate cancer is one of the most common malignancies in males worldwide. Serum prostate-specific antigen is a frequently employed biomarker in the diagnosis and risk stratification of prostate cancer; however, it is known for its low predictive accuracy for disease progression. New prognostic biomarkers are needed to distinguish aggressive prostate cancer from low-risk disease. This study aimed to identify and validate potential prognostic biomarkers of prostate cancer.
Two prostate cancer datasets from the Gene Expression Omnibus were analyzed to identify differentially expressed genes between benign prostatic hyperplasia (BPH) and prostatic carcinoma. Immunohistochemistry was used to evaluate the JUNB proto-oncogene, a subunit of the AP-1 transcription factor (JUNB), in 70 prostate cancer patients and 10 BPH samples.
Our findings showed that JUNB was significantly enriched in prostate cancer-related pathways and biological processes. JUNB expression was considerably higher in prostatic adenocarcinoma patients than in BPH patients. Regarding JUNB expression in prostate cancer cases, lower levels of JUNB expression were associated with higher grades of prostatic adenocarcinoma. Lower JUNB expression was associated with a higher risk of prostatic adenocarcinoma progression and shorter overall survival.
These results suggest that JUNB is a promising prognostic biomarker and a potential tumor suppressor in prostate cancer.
前列腺癌是全球男性中最常见的恶性肿瘤之一。血清前列腺特异性抗原是前列腺癌诊断和风险分层中常用的生物标志物；然而，其对疾病进展的预测准确性较低。需要新的预后生物标志物来区分侵袭性前列腺癌和低风险疾病。本研究旨在识别和验证前列腺癌潜在的预后生物标志物。
分析来自基因表达综合数据库的两个前列腺癌数据集，以确定良性前列腺增生（BPH）和前列腺癌之间的差异表达基因。采用免疫组织化学方法对70例前列腺癌患者和10例BPH样本中的JUNB原癌基因（AP-1转录因子的一个亚基，JUNB）进行评估。
我们的研究结果表明，JUNB在前列腺癌相关通路和生物学过程中显著富集。前列腺腺癌患者中JUNB的表达明显高于BPH患者。就前列腺癌病例中的JUNB表达而言，较低水平的JUNB表达与较高分级的前列腺腺癌相关。较低的JUNB表达与前列腺腺癌进展风险较高和总生存期较短相关。
这些结果表明，JUNB是一种有前景的预后生物标志物，也是前列腺癌中一种潜在的肿瘤抑制因子。
